Robot-assisted laparoscopic augmentation ileocystoplasty and Mitrofanoff appendicovesicostomy in children: Step-by-step and modifications to UChicago technique

Brittany Adamic1 | Lakshmi Kirkire2 | Ciro Andolfi1 | Craig Labbate1 | Joshua Aizen1 | Mohan Gundeti1

Abstract

Objective: To describe the step-by-step techniques and modifications for robot-assisted augmentation ileocystoplasty and Mitrofanoff appendicovesicostomy in a pediatric population with updated institutional results.

Introduction: Robot-assisted laparoscopic augmentation ileocystoplasty (RALIMA) protects the upper urinary tract and reestablishes continence in patients with refractory neurogenic bladder. Robotic assistance could provide the benefits of minimally invasive surgery without the challenges of pure laparoscopy. Here, we focus on the outcomes of RALIMA with salient tips and modifications of the technique.

Methods: We performed a retrospective review of our robotic database and identified 24 patients who underwent attempted robot-assisted laparoscopic augmentation ileocystoplasty (RALI) between 2008 and 2017 by a single surgeon at an academic center. Outcomes of interest included operative time, hospitalization time, postoperative complications, and change in bladder capacity. RALI and all concomitant procedures were performed using the da Vinci® surgical system (Intuitive Surgical, Sunnyvale, CA, USA).

Results: Of 24 patients, 20 successfully underwent RALI. Eighty percent underwent concomitant appendicovesicostomy (APV), 40% underwent antegrade continence enema channel formation (ACE), and 30% underwent a bladder neck procedure. Mean operative time was 573 minutes and the most recent RALIMA was 360 minutes. The average return to regular diet was 3.9 days and length of stay was 6.9 days. Mean change in bladder capacity was 244% postoperatively. Thirty-day complications were noted in 35% of patients; one Clavian grade I (5%) complication, five grade II (25%) complications, and one grade IIIb (5%) complication. With a median follow-up of 83.1 months we note a 25% incidence of bladder stones, 15% upper tract stones, 5% incidence of bladder rupture, and 5% small bowel obstruction. No patients required re-augmentation in the follow-up period.
INTRODUCTION

Augmentation ileocystoplasty is necessary to protect the upper tracts in patients who fail medical management of their neurogenic bladders. Indications include severe hydronephrosis and/or concerning urodynamic parameters such as detrusor leak point pressure ≥40 cm H₂O in patients who have failed medical management. Augmentation ileocystoplasty leads to decreased voiding pressures as well as increased bladder capacity and continence. The majority of patients undergoing this procedure have neurogenic bladder or valve bladder due to posterior urethral valves. Additional abnormalities that account for the condition include the spectrum of spina bifida. In the majority of cases, augmentation ileocystoplasty is coupled with the creation of a continent catheterizable channel (CCC) which allows for patients to achieve social continence and to avoid urethral catheterization. Urethral catheterization can ultimately cause discomfort in a sensitive urethra as well as complications such as trauma, strictures, and eventually patient noncompliance. Most often, the appendix is used for the CCC (Mitrofanoff appendicovesicostomy) but another common technique is using a transversely tubularized segment of bowel as a channel (Yang-Monti technique).

Augmentation ileocystoplasty is traditionally performed as an open procedure. While a laparoscopic approach has been described, the steep learning curve has prevented its incorporation into widespread practice. Since the later introduction of the robotic approach, it has been increasing in prevalence although the technical demands of the operation limit universal adoption.

We present an updated technical demonstration video of RALIMA on a pediatric patient, with step-by-step methodology of the operation with modifications since its inception in 2008 (UChicago technique) as well as updated long-term outcomes at our institution.

SURGICAL TECHNIQUE

*Indicates modified technique.

Preoperative preparation

We do not use a bowel preparation preoperatively. Patients are encouraged to continue a regular diet until midnight the night before surgery. Patients are admitted to the hospital postoperatively on the day of surgery. A preoperative antibiotic protocol of weight-based cefazolin, metronidazole, and gentamicin is administered within the 30 minutes before skin incision and are continued for 24-48 hours. Patients with ventriculoperitoneal shunts also receive one dose of prophylactic vancomycin preoperatively. A neurosurgery consult is obtained prior to surgery for these patients.

Patient positioning, port placement, and robot docking

The patient is positioned in a supine semilithotomy with 10 degrees Trendelenburg. A Foley catheter is placed steriley on the field. A nasogastric tube is inserted for the duration of the surgical procedure. A 12-mm camera port is placed in a supraumbilical position using Hasson’s technique.* We have previously described umbilical camera port placement; however, we find the supraumbilical port placement allows for easy identification and dissection of the appendix and bowel. If utilizing the DaVinci X or Xi® robot, an 8-mm camera port is placed in a similar position. After establishing pneumoperitoneum, the 8-mm robotic working arm ports are placed laterally at the level of the umbilicus in the midclavicular line. A 5-mm assistant port is placed in the left upper quadrant, inferior to the costal margin and in the midclavicular line (this can be substituted for a large assistant port if staples are utilized for bowel anastomosis). A fourth robotic working arm port can be placed at the site of stoma creation in the right iliac fossa for patients who are greater than 12 years of age or 5 feet tall due to space restriction.

Diagnostic peritoneoscopy

We recommend beginning the case with diagnostic peritoneoscopy and lysis of adhesions if necessary. This step facilitates the ease of appendix isolation, especially the suprahepatic locations in patients with VP shunts. If present, a VP shunt can be placed into an endocatch bag. The appendix is identified, ensuring adequate length and vascularity to allow for successful appendicovesicostomy. The evaluation of the appendix and intra-abdominal anatomy allows for open conversion if required prior to docking the

Conclusions: RALI has similar functional outcomes and complications when compared with the open augmentation ileocystoplasty literature. RALI is desirable due to favorable pain control with decreased length of stay. Long-term outcomes after RALI are similar to the open approach. As the operative time is currently the largest point of criticism with the robotic approach, we discuss modifications to decrease the operative time.

KEYWORDS

augmentation ileocystoplasty, neurogenic bladder, pediatric, robotic
robot. If appropriate expertise is available, a Monti channel can be created robotically.

2.4 | Appendiceal isolation and harvest

A traction suture can be placed at the tip of the appendix to aid in dissection and manipulation. A 4-0 Vicryl suture (polyglactin) is placed as a stay suture and a mesenteric window with adequate blood supply is developed. The appendix is then excised from the cecum. If a short appendix is noted, a cecal flap can be created to ensure adequate length and to avoid stomal stenosis.* In those who require antegrade continence enema channel creation, the length of the appendix will determine the need for a split technique vs a cecal flap. The defect in the cecum is closed in two layers.

2.5 | Ileal loop isolation and anastomosis

A 20-cm ileal segment is isolated 20 cm proximal to the ileocecal junction for the cystoplasty patch. Percutaneous stay stitches placed in the proximal and distal ends of the bowel are performed with Keith needles. This maneuver provides traction of the bowel and allows for easier isolation and anastomosis. A premeasured umbilical tape is used to ensure accurate measurement of the bowel segments. After ensuring mesenteric length and that the ileal segment will reach the bladder, the ileal loop is transected. We demonstrate the division of the mesentery with Harmonic scalpel® and bipolar forceps to reduce bleeding and facilitate the dissection.

Bowel continuity is re-established by hand sewn single-layer seromuscular anastomosis using 5-0 PDS in children, or 4-0 PDS in adults. We start the anastomosis on the antimesenteric border using a running stitch toward the mesentery on the posterior wall. On the anterior wall of the bowel, a separate stitch is run from the mesenteric border toward the antimesenteric border. The mesenteric defect is closed to prevent the possibility of closed loop bowel obstruction.

2.6 | Detrusorotomy and extravesical appendicovesicostomy

In the case of a short appendix (as such in the video), an oblique extravesical appendicovesicostomy with stoma formation in the right iliac fossa can be created. Otherwise, we suggest the intravesical approach with posterior wall implantation to reduce the operative time.* The detrusorotomy can be made in the coronal plane to reduce bleeding.* When performing the intravesical approach, the appendix is brought to the posterior wall and oriented according to planned stoma site creation (umbilical location proceed with midline anastomosis, while right iliac fossa requires an oblique appendectomy). The bladder is distended with sterile saline and a detrusorotomy is made along the posterior bladder wall in the coronal plane. The previously placed stay suture at the tip of the appendix allows for easy manipulation while minimizing direct handling of the appendix. The appendix is spatulated and anastomosed to the bladder mucosa with interrupted 5′0 PDS II® Medline Industries (polydioxanone) stitches. An 8 French feeding tube is placed within the appendix. After the anastomosis is performed, the detrusor muscle is closed over the appendix with 3-0 or 4-0 Vicryl in continuous fashion without tightening. We do not fenestrate the mesentery or tack the appendix to the bladder wall.

2.7 | Ileal detubularization

The previously isolated ileal segment is now detubularized along the antimesenteric border with a harmonic scalpel*. This allows for a reduction in operative time by reducing the bleeding. Stay sutures are placed at the proximal and distal ends of the ileal patch to prevent torsion of the mesentery.

2.8 | Cystotomy and patch ileoystoplasty

The cystotomy is performed in the coronal plane. A thick-walled bladder is often encountered, and we find the harmonic scalpel aids in hemostasis and decreases operative time compared to our previous use of monopolar scissors.* We then turn attention to the augmentation with ileal patch. The detubularized bowel is sutured to the apices of the cystotomy. Utilization of the 4th arm can aid in retraction and exposure. We now use a barbed quill suture to perform the posterior bowel bladder anastomosis in a continuous fashion.* We utilize either a 2-0 QuillTM suture (Surgical specialties corporation), Vicryl, or polydioxanone (PDS). In our experience, placement of only one suprapubic catheter often leads to dislodgement and clogging; therefore, two suprapubic catheters are placed percutaneously to provide maximal drainage.* The anterior bladder bowel anastomosis is then performed, working from the apices toward the midline. The augmented bladder is filled with sterile water to identify leakage.

2.9 | Maturation of appendix stoma to right iliac fossa

The appendix can be brought to the predetermined stoma site with the assistance of a stay suture. A skin flap (V, VQ, VQZ technique) is created and anastomosed to the Mitrofanoff appendicovesicostomy (MAPV) using 5-0 PDS II® Medline Industries (polydioxanone) suture. The fascia of the remaining port sites is closed with 2-0 Vicryl suture under direct vision and the skin is closed with 5-0 Monocryl® Ethicon (poliglecaprone) or equivalent suture.

2.10 | Postoperative management

All catheters (two suprapubic catheters and one urethral catheter) are left to freely drain for 4 weeks. The appendicovesicostomy catheter
| Age at surgery (years) | Gender | Weight (kg) | Pathology                                | OR time (mins) | Additional procedure | Preoperative bladder capacity (mL) | Postoperative bladder capacity (mL) | Regular diet (days) | Length of stay (days) | 0-30-day complications | 30-90-day complications | >90-day complications | Follow up (mos) | Secondary surgery |
|-----------------------|--------|-------------|------------------------------------------|----------------|----------------------|----------------------------------|----------------------------------|---------------------|----------------------|-----------------------|------------------------|------------------------|----------------|-------------------|
| 14.8                  | Male   | 44.2        | PUV                                      | 379            | APV                  | 618                             | 600                              | 6                   | 7                    | UTI                   | UTI                    | UTI                    | 35.7           | Mitrofanofscopy (1) |
| 8.8                   | Female | 28.6        | Sacral agenesis                          | 480            | ACE, APV             | 90                              | 400                              | 4                   | 6                    | None                  | None                   | UTI                    | 11.2           | ACE deflux (6), Mitrofanofscopy (12), ACE takedown (7) |
| 14.2                  | Male   | 44.5        | Spina bifida, sacral agenesis            | 573            | ACE, APV             | 171                             | 600                              | 14                  | 16                   | pSBO requiring TPN and NGT, UTI | Bladder perforation | Bladder stone         | 41.9           | Endoscopic cystolitholapaxy (8), Mitrofanofscopy (21) |
| 14.9                  | Male   | 54.4        | Myelomeningocele                         | 512            | ACE, Urethral Sling  | 229                             | 500                              | 3                   | 8                    | None                  | None                   | Urethral sling erosion | 36.3           | Removal eroded sling and urethropoplasty (10), SPT and bladder neck deflux (12), pyeloplasty (31) |
| 15.6                  | Male   | 56.7        | Myelomeningocele                         | 506            | ACE, APV             | 180                             | 500                              | 4                   | 7                    | UTI                   | None                   | UTI                    | 17             | None |
| 9.3                   | Female | 24.6        | Meningomyelocele                         | 509            | ACE, APV             | 105                             | 300                              | 4                   | 6                    | None                  | UTI, difficulty catheterizing | UTI, difficulty catheterizing | 28.3          | Mitrofanofscopy (2), Open Monti channel creation (54) |
| 13.8                  | Female | 72.8        | Myelomeningocele, open bladder neck      | 659            | APV, BNC             | 50                              | 275                              | 3                   | 6                    | None                  | None                   | UTI                    | 81.4           | PCNL (82) |
| 25.6                  | Male   | 56.7        | Sacral agenesis, open bladder neck, high-level imperforate anus | 708           | Urethral Sling       | 46                              | 350                              | 2                   | 4                    | None                  | None                   | None                   | 28.6           | Umbilical Sinus exploration (24) |
| 11.8                  | Male   | 36.3        | Tethered cord, poor compliance, open bladder neck | 532           | APV, BNC, circumcision | 87                              | 400                              | 5                   | 7                    | Bladder neck dehiscence | None                   | None                   | 95.6           | Mitrofanofscopy and SPT (<1), Bladder neck closure (3), Stomal polyp excision-skin level (59) |
| 7.6                   | Male   | 34.5        | Myelomeningocele, open bladder neck      | 923            | APV, ACE, BNC        | 140                             | 250                              | 6                   | 8                    | None                  | None                   | UTI, bladder neck dehiscence | 96.7           | Bladder neck closure (36), Endoscopic cystolitholapaxy (62) |

(Continues)
| Age at surgery (years) | Gender | Weight (kg) | Pathology | OR time (mins) | Additional procedure | Preoperative bladder capacity (mL) | Postoperative bladder capacity (mL) | Regular diet (days) | Length of stay (days) | 0-30-day complications | 30-90-day complications | >90-day complications | Follow up (mos) | Secondary surgery (mos) |
|----------------------|--------|-------------|-----------|---------------|---------------------|---------------------|---------------------|---------------------|---------------------|------------------------|------------------------|----------------------|------------------|------------------------|
| 11.7 Female 34.3 | Myelomeningocele, open bladder neck | 654 | APV, ACE, BNC | 60 | 500 | 2 | 4 | None | None | UTI, bladder neck dehiscence, bladder stone | 86.9 | Bladder neck closure, re-do ACE (21) Attempted staged endoscopic cystolitholapaxy (32), Open cystolitholapaxy (33) |
| 11.8 Male 65.7 | Posterior Urethral Valves | 467 | APV | 450 | 550 | 4 | 5 | None | None | UTI | 84.9 | Kidney transplant (22), Mitrofanoffscopy (47) |
| 7.7 Male 25.2 | Myelomeningocele | 627 | ACE | 90 | 300 | 3 | 7 | None | None | Urethral leakage of urine (large bladder neck requiring multiple procedures), bladder stone | 117.6 | Bladder neck deflux (5.6), Monti channel, Bladder neck reconstruction and Bilateral ureteral reimplantation (12), Bladder neck closure (20), Endoscopic cystolitholapaxy (10,70,102) Open cystolitholapaxy (48, 55, 97) |
| 7.4 Male 23.4 | Tethered cord | 711 | APV | 110 | 700 | 4 | 7 | Ileus | None | UTI, keloid formation, parastomal hernia | 120.1 | Mitrofanoffscopy (1.1, 13), Stoma revision (3.4), Parastomal Hernia repair (33) |
| 11.8 Female 34 | Sacral agenesis | 610 | APV | 170 | 300 | 1 | 6 | None | difficulty catheterizing | UTI, APV leakage | 126.2 | Mitrofanoffscopy (1.6), Deflux into APV (12) |
| 10.4 Female 40 | Myelomeningocele | 609 | APV | 250 | 450 | 1 | 8 | SSI, Paresthesia | None | UTI, stomal stenosis, keloid formation, false passage | 129.4 | Stoma revision (5.18), Mitrofanoffscopy (17, 17, 37, 42) |
is capped and secured to the abdomen. At 4 weeks postoperation, the MAPV catheter is removed and the patient/family is taught clean intermittent catheterization (CIC). The suprapubic catheters are removed after the patient/family has shown competence in performing CIC.

3 | METHODS

After obtaining approval from our institutional IRB, we identified patients who underwent robot-assisted laparoscopic ileocystoplasty (RALI) at our institution between 2008 and 2017 by a single surgeon. Four patients were excluded due to conversion to open surgery. Preoperative videourodynamics and renal ultrasounds were performed on all patients, with adjunctive imaging, such as VCUG and DMSA scans as indicated postoperatively; serial renal ultrasounds and metabolic evaluation were also performed on all patients. Urodynamics and any adjunctive tests were used as needed. Demographic information, preoperative UDS findings, operative details, and postoperative outcomes including complications were recorded and are described.

4 | RESULTS

A total of 24 patients were scheduled to undergo RALI; however, four were converted to open surgery and therefore excluded from the final analysis. Reasons for open conversion include two patients with kyphosis limiting intra-abdominal space on insufflation and two patients with dense adhesions and unfavorable appendiceal anatomy. Table 1 displays patient characteristics. The median age was 11.7 years old and 60% of patients were male. The median weight in kilograms was 44.3 and median BMI was 19.9. Eight patients (40%) had VP shunts. Only two patients (10%) had a history of posterior urethral valves (PUV). Table 2 depicts perioperative details. Mean operative time was 573 minutes; however, this is difficult to quantitate due to 11 patients undergoing concomitant procedures. Operative time includes skin incision and ends after skin closure and includes docking of the robot. Our most recent patient underwent RALIMA with an operative time of 360 minutes. Mean time to regular diet was 3.9 days and mean length of stay was 6.9 days. Mean change in bladder capacity was increased by 244% postoperatively which is displayed in Table 3.
TABLE 3 Change in Bladder Capacity

| Change in bladder capacity                        |          |
|--------------------------------------------------|----------|
| Preoperative capacity, mL (95% CI)               | 214 (106-322) |
| Percent of expected (95% CI)                     | 51 (30-72)  |
| Postoperative capacity, mL (95% CI)              | 437 (380-494) |
| Percent change capacity (95% CI)                 | 244 (143-345) |

TABLE 4 Complications

| Any complication | N (%) | Complication                        |
|------------------|-------|-------------------------------------|
| 30 day            | 7 (35)|                                     |
| 30-90 day         | 6 (30)|                                     |
| 30-day complication |       |                                     |
| None              | 13 (65)|                                   |
| Grade I           | 1 (5) | Ileus (1)                             |
| Grade II          | 5 (25)| UTI (2)                              |
|                   |       | Surgical site infection (1)          |
|                   |       | Partial small bowel obstruction (1)  |
|                   |       | Deep vein thrombosis (1)            |
| Grade III         | 1 (5) | Bladder neck dehiscence (1)         |
| 30-90-day complication |     |                                     |
| None              | 15 (75)|                                   |
| Grade I           | 0 (0) |                                     |
| Grade II          | 3 (15)| UTI (3)                              |
| Grade III         | 5 (25)| Bladder perforation requiring IR drainage (1) |
|                   |       | Difficulty catheterizing requiring mitrofanoscopy (4) |

FIGURE 1 Long-Term Complications

(12.5%) ACE patients underwent ACE take down due to patient preference. No patients required repeat augmentation.

5 | DISCUSSION

The robotic approach has been favored over open for decreased pain, cosmesis, and improved tissue handling without compromising outcomes across many pediatric operations. The laparoscopic approach to augmentation cystoplasty has not been widely accepted due to steep learning curve and increased operative time. Robot-assisted surgery offers the ability to shorten the learning curve and allow minimally invasive surgery to become accessible even in more complex reconstructive procedures. RALI have been shown to decrease postoperative opioid use when compared to open equivalent as well as a trend toward decreased length of stay.

Although RALI has its advantages, appropriate patient selection is key. Anatomic considerations, such as kyphosis leading to poor intra-abdominal space, prior surgery leading to dense adhesions, and appendiceal anatomy can necessitate open conversion. The patient population requiring this surgery often may be wheelchair bound or have contractures, further leading to difficulty positioning. In our series we describe one patient who had a brief neuropraxia attributed to positioning. Additionally, unforeseen compliance issues regarding catheterization can lead to complications following this complex operation. Multiple complications in our series are the result of noncompliance with catheterization.

Postoperative considerations in this unique patient population regarding pain management must be considered. Many of these patients are unable to receive epidural or spinal anesthesia due to spinal dysraphism and, therefore, rely on pain control regimens which may include opioids. There are concerns that pain control regimens relying on opioids may lead to pulmonary complications as these patients often have comitant restrictive lung disease due to kyphoscoliosis. We favor robotics for improved postoperative pain control.

Concomitant procedures can be performed at time of RALI. In our series we describe eight patients who underwent ACE channel
Creation and six who underwent bladder neck closure or sling placement. These procedures lengthen operative time and make it difficult to assess the amount of time required to complete RALI specifically. Additional patient characteristics which lead to high variability in surgical time include patients with previous surgeries, especially patients with VP shunts, and patients with a high BMI. In our series, 40% (n = 8) had VP shunts which are associated with dense abdominal wall adhesions leading to increased operative time for adhesiolysis. The median BMI in this series was 19.9, which included three overweight patients (BMI 25-29.9) and three patients classified as obese (BMI > 30).

RALIMA appears to be safe with comparable complication rates to the open equivalent. In this series, we report a 35% 30-day complication rate compared to previously reported 62% for open surgery at our institution, of which 31% and 31% were grade I and III complications, respectively. Similar rates of 30-90-day complications were observed. Within this time period, 25% of RALI patients had complications compared to 46% open complications. Of the 25% who had complications after RALI, 15% had Clavien grade II and 25% grade III compared to open 23% clevian grade 1, 8% grade 2, and 15% grade III.

With a median follow-up of 83.1 months, we note a 25% incidence of bladder stones, 15% upper tract stones, 5% incidence of bladder rupture, and 5% small bowel obstruction which is similar to previously reported data from a large database with a 10-year follow-up period as displayed in Figure 2. Bladder capacity was increased on average 244% in this series. RALIMA patients did not require re-augmentation, compared to reports of 5.2-13.4% of open operations requiring re-augmentation.

Operative times, although improving with increased experience, continue to be longer than the open alternative. The unique variability of procedures/anatomy and complexity of each patient makes it challenging to report and predict a uniform operative time. Our operative time has decreased from our first case, 623 minutes, to our most recent case, 360 minutes. Despite improvements in operative technique, the open alternative at our institution remains significantly shorter with 287 minutes of mean operative time.

Contemporary open augmentation enterocystoplasty times are not readily available in the literature. However, one group noted an average of 234 minutes for extraperitoneal approach and 336 minutes for intraperitoneal approach. Analysis of the NSQIP data by McNamara et al revealed a median operative time of 426 minutes for augmentation ileocystopasty with appendicovesicostomy, 318 minutes for an augmentation alone, and 234 minutes for appendicovesicostomy only. Although operative time remains the major criticism of the robotic approach, with increasing experience, this gap is closing.

The following modifications have enabled a shorter operative time as displayed in Figure 3. The supraumbilical camera port placement allows for easier handling of the bowel and appendix. The use of the harmonic scalpel has improved operative times when performing the cystotomy, detubularizing the ileum and dividing the mesentery. We find the use of this device has superior hemostasis when compared to the monopolar/bipolar robotic energy sources. Making the detrusorotomy in the coronal plane is another way to decrease bleeding and therefore operative time. Utilizing a port site for the APV can also aid in decreasing operative time. Additionally, percutaneous bowel stay sutures and traction stitches allow for easier and faster bowel anastomosis. We prefer a running hand-sewn anastomosis when compared to the monopolar/bipolar robotic energy sources.

FIGURE 3 Modifications to UChicago technique
REFERENCES

1. Gundeti MS, Petravick ME, Pariser JJ, Pearce SM, Anderson BB, Grimsby GM, et al. A multi-institutional study of perioperative and functional outcomes for pediatric robotic-assisted laparoscopic Mitrofanoff appendicovesicostomy. J Pediatr Urol. 2016;12:386.e1–5.

2. Cohen AJ, Brodie K, Murthy P, Wilcox DT, Gundeti MS. Comparative outcomes and perioperative complications of robotic vs open cystoplasty and complex reconstructions. Urology. 2016;97:172–8.

3. Lorenzo AJ, Cerveira J, Farhat WA. Pediatric laparoscopic ileal cystoplasty: complete intracorporeal surgical technique. Urology. 2007;69:977–81.

4. Gundeti MS, Eng MK, Reynolds WS, Zagaja GP. Pediatric robotic-assisted laparoscopic augmentation ileocystoplasty and Mitrofanoff appendicovesicostomy: complete intracorporeal–initial case report. Urology. 2008;72:1144–7.

5. Gundeti MS, Godbole PP, Duncan TW. Is bowel preparation required before cystoplasty in children? J Urol. 2006;72:1574–7.

6. Leys CM, Austin MT, Pietsch JB, Lovvom HN. Elective intestinal operations in infants and children without mechanical bowel preparation: a pilot study. J Pediatr Surg. 2005;40:978–81.

7. Shah M, Ellis CT, Phillips MR, Marzinsky A, Adamson W, Weiner T, et al. Preoperative bowel preparation before elective bowel resection or ostomy closure in the pediatric patient population has no impact on outcomes: a prospective randomized study. Am Surg. 2016;82:801–6.

8. Sorensen MD, Delostrinos C, Johnson MH, Grady RW, Lendvay TS. Comparison of the learning curve and outcomes of robotic assisted pediatric pyeloplasty. J Urol. 2011;185:2517–22.

9. Barbosa JABA, Barayan G, Gridley CM, Sanchez DCJ, Passerotti CC, Houck CS, et al. Parent and patient perceptions of robotic vs open urological surgery scars in children. J Urol. 2013;190:244–50.

10. Varda BK, Johnson EK, Clark C, Chung BI, Nelson CP, Chang SL. National trends of perioperative outcomes and costs for open, laparoscopic and robotic pediatric pyeloplasty. J Urol. 2014;191:1090–6.

11. Docimo SG, Moore RG, Adams J, Kavoussi LR. Laparoscopic bladder augmentation using stomach. Urol Ann. 1995;46:565–9.

12. Barashi NS, Rodriguez MV, Packiam VT, Gundeti MS. Bladder reconstruction with bowel: robot-assisted laparoscopic ileocystoplasty with Mitrofanoff appendicovesicostomy in pediatric patients. J Endourol. 2018;32:119–26.

13. Murthy P, Cohen JA, Selig RB, Gundeti MS. Robotic-assisted laparoscopic augmentation ileocystoplasty and Mitrofanoff appendicovesicostomy in children: updated interim results. Eur Urol. 2015;68:1069–75.

14. Schlomer BJ, Copp HL. Cumulative incidence of outcomes and urologic procedures after augmentation cystoplasty. J Pediatr Urol. 2014;10:1043–50.

15. McNamara ER, Kurtz MP, Schaeffer AJ, Logvinenko T, Nelson CP. 30-day morbidity after augmentation enterocystoplasty and appendicovesicostomy: a NSQIP pediatric analysis. J Pediatr Urol. 2015;11:209.e1–6.

How to cite this article: Adamic B, Kirkire L, Andolfi C, Labbate C, Aizen J, Gundeti M. Robot-assisted laparoscopic augmentation ileocystoplasty and Mitrofanoff appendicovesicostomy in children: Step-by-step and modifications to UChicago technique. BJUI Compass. 2020;1:32–40. https://doi.org/10.1002/bco2.7